Clinical Trials Browser

Phase 3 × Neoplasms by Site × Genitourinary × Clear all

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

NCT04225299 2020-11-13

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT01310894 2019-07-11

PCM301

Phase 3 Completed

413 enrolled

Genitourinary

Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Phase 3 Terminated

1 enrolled 5 charts

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT02254915 2015-04-01

SHTC-EUROPE-1

Phase 3 Withdrawn

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT00384891 2014-10-07

Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer

Phase 3 Terminated

190 enrolled

Genitourinary

Hyperthermia, Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Neoplasms, Neoplasms by Site, Urologic Diseases, Urologic Neoplasms

Clinical Trials

Savolitinib vs. Sunitinib in MET-driven PRCC.

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

PCM301

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

SHTC-EUROPE-1

Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer